Association of dietary inflammatory index with body composition and disease progression in adults with amyotrophic lateral sclerosis: evidence from a cross-sectional study Authors: Hamid Abbasi, Hamid Rasekhi, Mehrnoosh Shafaatdoost, Arefeh Mohajerani, Milad Asadollahi, Maryam Rashidi, Mahsa Malekahmadi, Payam Sarraf Published: 2026 ABSTRACT BackgroundFor decades, diet’s pro-inflammatory properties have been considered a potential risk factor in the onset of amyotrophic lateral sclerosis (ALS). This study aimed to explore the association of dietary inflammatory index (DII) with body composition and disease progression in adult individuals with ALS.MethodsClinically stable adults aged 18 years and older were enrolled for this study from the neuromuscular disorders clinic at Imam Khomeini Hospital. All participants met the EI Escorial criteria for ALS. Participants completed a 153-item dish-based semi-quantitative food frequency questionnaire (FFQ), which was developed and validated for Iranian adults. Multiple linear regression analyses were performed to examine the association between DII and the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R), Medical Research Council (MRC) score, disease progression rate (DPR), and body composition among adult participants with ALS.ResultsThis cross-sectional study involved 93 adult participants with ALS, comprising 29 women and 64 men (aged 56.95 ± 12.05 years). Participants in the third DII tertile had significantly reduced consumption of several nutrients, comprising vitamin E (P < 0.001), vitamin A (P < 0.001), vitamin B6 (P < 0.001), folic acid (P = 0.006), vitamin K (P < 0.001), fluoride (P = 0.009), potassium (P < 0.05), and selenium (P = 0.003). DPR displayed a significant negative association with the third tertile of DII (β T3 vs. T1= -1.1, 95CI%:-2.2, -0.04; Ptrend= 0.04), signifying a significant relationship after accounting for confounders, including age, gender, BMI, physical activity, and history of ALS.ConclusionOur findings suggest that higher inflammatory dietary patterns might be associated with a slower rate of disease progression in adults suffering from ALS. To elucidate these findings, randomized controlled trials are warranted.Supplementary InformationThe online version contains supplementary material available at 10.1186/s40795-026-01336-x. Introduction Amyotrophic lateral sclerosis (ALS), also termed as Lou Gehrig’s disease, is an incurable and pervasive neurodegenerative disorder identified by the engagement of both superior and inferior motor dysfunction, resulting in a broad spectrum of motor and non-motor manifestations [1]. ALS’s clinical symptoms encompass muscular atrophy, dysphagia, shortness of breath, dysarthria, limb paralysis, and eventually pulmonary failure resulting in death [2]. The ALS prevalence has been estimated from 2.6 to 3.0 cases per 100,000 individuals, considering the poor survival rate of 30 months [3, 4]. Traditionally, ALS subtypes have been classified into either sporadic variant (roughly 90–95%), which occur due to environmental risk factors and are widely affected by genetic factors, or familial variant (approximately 5–10%), which predominantly result from a dominant pattern of autosomal inheritance [5, 6]. Indeed, in congruence with recent evidence, a balanced diet and a healthy lifestyle have been significantly linked to both the management and prevention of ALS [7–10]. Evaluating the total quality of a diet, instead of concentrating on individual nutritional groups, is proposed as a potentially superior method for examining the links between diet and disease. The dietary inflammatory index (DII) is a new scoring system that calculates the potential of inflammation in an individual’s diet, taking into account the inflammatory characteristics of assorted dietary components. Furthermore, the DII has been generally validated with a variety of both anti-inflammatory markers (such as interleukin-4 (IL-4), and interleukin-10 (IL-10)) and pro-inflammatory markers (including interleukin-6 (IL-6), tumor necrosis factor- α (TNF- α), C-reactive protein (CRP)) [11]. A diet abundant in fruits and vegetables, known for their anti-inflammatory properties, correlates with a reduced DII score [12]. Conversely, elevated intake of animal protein is linked to an increased DII score [13]. Park et al. demonstrated that an anti-inflammatory diet was related to prognosis, including survival time and disease progression in patients living with ALS [14]. Nutritional status and body composition can affect survival and prognosis. In a meta-analysis, Dardiotis et al. revealed that for each unit increase in body mass index (BMI), the hazard ratio for ALS survival drops by around 3% [15]. On the other hand, a meta-analysis displayed the effect of obesity and overweight on the risk of ALS, which revealed a significant 40% reduction in ALS risk [16]. During the natural course of the ALS disease, sarcopenia occurs due to denervation, malnutrition, and infectious complications such as aspiration pneumonia [17]. Thus, body composition gradually alters, leading to a decrease in BMI, fat-free mass (FFM), and phase angle, and an increase in fat mass (FM), and extracellular/intracellular water ratio [18]. Malnutrition, low-phase angle value, increased extracellular (ECW)/intracellular (ICW) water ratio, and reduced FFM are known as negative prognostic factors [19, 20]. Given this fatal disorder, causing nutritional and physical issues over time, and considering the necessity of nutrition on factors affecting the survival rate, this hospital-based cross-sectional study aimed to explore the role of DII in individuals living with ALS. Methods and materials Study design The sample size was estimated to be 91 patients using the study by Yu et al. with a type I error of 5% and a power of 80% [21]. This cross-sectional study involved 93 adult participants with ALS, comprising 29 women and 64 men, who were referred for general checkups to the neuromuscular disorder clinic of Imam Khomeini Hospital Complex, affiliated with Tehran University of Medical Sciences, Tehran, Iran. The participants were selected based on neurological examinations and diagnoses according to the EI Escorial criteria [22, 23], conducted by a neurologist specialized in neuromuscular diseases. Adults aged 18 and above were included in this study, while exclusion criteria encompassed conditions like recent pregnancy, lactation, and pediatrics. Patients had to be fed orally, and patients who were fed through a tube or intravenously were not included in the study. A certified nutritionist conducted all phases of recruitment and data collection through one-on-one interviews. This study was approved by the Ethics Committee of Tehran University of Medical Sciences and Health Services, Neuroscience Institute, Tehran (protocol code IR. TUMS.NI.REC.1401.059). The Participants completed a written consent before being included in the study. General characteristics and anthropometric assessments Demographic information was obtained through a questionnaire that included variables such as age, gender, and ALS history. Physical activity level is calculated using the metabolic equivalent (https://metscalculator.com/). An expert researcher administered all anthropometric surveys in a single day for each participant. Body composition was assessed using bioelectrical impedance analysis (BIA) (Inbody s10). Height and weight measurements were taken using a wall-mounted stadiometer and a wheelchair scale (Seca Co., Hamburg, Germany), with results rounded to the nearest 0.5 cm and 0.1 kg, respectively. In cases where standing height measurement was not possible, ulna length was used to estimate height. Additionally, mid-arm circumference (MAC) was measured in adults to the nearest 0.1 cm using a flexible, non-stretch tape positioned midway between the acromion and olecranon processes on the shoulder blade and the ulna, respectively. Dietary assessments Participants completed a 153-item dish-based semi-quantitative food frequency questionnaire (FFQ) in the Willett format, which was specifically developed and validated for Iranian adults [24]. This FFQ covered response options, with portion sizes also recorded. Based on the FFQ data, daily nutrient intake was calculated by multiplying the consumption frequency of each food item by its nutrient content. Nutrient intakes were determined using the US Department of Agriculture (USDA) national nutrient databases and Iran’s Food Composition Tables [25, 26]. To adjust for total caloric intake, linear regression models were employed to calculate the residuals of nutrient intake. These residuals were then standardized and utilized in all subsequent analyses. Clinical and functional measurements For assessing functional scores, we utilized the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R). This scale consists of 12 items categorized into four domains: bulbar function, fine motor function, gross motor function, and respiratory function. Each item is scored on a scale from 0 to 4, resulting in a total score ranging between 0 and 48, with higher scores indicating less disability [27]. Additionally, the Medical Research Council (MRC) score is determined by evaluating six bilateral movements of both superior and inferior limbs. Strength is graded from zero (plegia) to five points (normal strength), with a maximum possible score of 60 points, as detailed by Kleyweg et al. [28]. An MRC score below 48 indicates muscular weakness, according to Connoly et al. [29]. Calculation of dietary inflammatory index To compute the DII, the intake of each food component is standardized against a global intake database, encompassing 11 datasets that represent diverse diets across various populations [30]. A z-score for each food component is calculated by subtracting the global standard mean from the actual food intake and dividing the difference by the global reference standard deviation. To minimize the effect of right skewing, the z-score is converted to percentile scores, which are then doubled and adjusted by subtracting “1” to achieve a symmetric distribution centered on o (null) and bounded between − 1 and + 1. These centered percentiles are multiplied by the “food parameter-specific inflammatory effect score” provided by Shivappa et al. [30]. The resulting food parameter-specific inflammatory effect scores are then summed to derive the overall DII scores for each individual. The theoretical range of DII scores, considering all food components, spans from − 8.87 to 7.98, representing maximally anti-inflammatory to maximally pro-inflammatory diets, respectively. Thirty-three dietary components and food items, including twenty-four anti-inflammatory constituents and nine pro-inflammatory components, were utilized to compute the DII score (Supplementary Table 1). To mitigate the impact of varying energy intake among participants with ALS, energy-adjusted values were calculated using the nutrient density method [31]. Statistical analyses Normality of the data was checked by the Kolmogorov–Smirnov test. Tertile cutoff points for the DII were determined and adjusted for caloric intake. Differences in continuous variables were assessed using the Analysis of Variance (ANOVA) test and the Kruskal-Wallis H test, while chi-square tests evaluated the distributions of categorical variables. Age and gender-adjusted nutrient intakes across DII tertiles were analyzed using Analysis of Covariance (ANCOVA). Multiple linear regression analyses were executed to explore the associations of continuous and categorical DII with body composition and disease progression among adult participants with ALS. The P-for-trend was estimated by assigning the median value of each DII tertile as a continuous variable. The disease progression rate (DPR) was calculated using the formula (\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\frac{48-ALSFRS-R}{Disease\:duration\:\left(months\right)}$$\end{document}), categorized as having slow (< 0.5), intermediate (0.5-1.0), and fast (> 1.0) progressive disease [32]. For variables that were normally distributed, Pearson’s correlation coefficient was used to evaluate the linear relationship between the DII and outcome measures. For variables that were not normally distributed, Spearman’s rank correlation coefficient was applied to assess monotonic associations. All correlation coefficients (r or ρ) are reported alongside their respective p-values. Statistical analyses were carried out using RStudio version 2025.05.0 alongside R version 4.3.3, with relevant R packages such as “lm,” “chisq.test,” “patchwork,” “aov,” “cor.test”, and “dietaryindex” employed for the analyses [33–36]. A two-sided P-value of ≤ 0.05 was considered statistically significant. Results Characteristics of adult individuals with ALS In this cross-sectional study, 93 adult individuals diagnosed with ALS were categorized into three groups based on their DII scores. The mean age of the participants was 56.95 years. As detailed in Table 1, significant differences were observed in parameters such as gender distribution (P < 0.05) and the duration of diagnosis (P = 0.005). In the highest DII tertile, where scores exceeded 0.21, the ratio of men to women was 83.87% to 16.13% (P < 0.05). Furthermore, participants within this tertile demonstrated a longer duration since diagnosis (P < 0.005). Table 2 indicated that individuals in the highest DII tertile had significantly reduced consumption of several nutrients, comprising vitamin E (P < 0.001), vitamin A (P < 0.001), vitamin B6 (P < 0.001), folic acid (P = 0.006), vitamin K (P < 0.001), fluoride (P = 0.009), potassium (P < 0.05), and selenium (P = 0.003). Table 1Study characteristics of ALS patients stratified by tertiles of the dietary inflammatory indexTotalN = 93a Dietary Inflammatory Index P-valuebT1n = 31aT2n = 31aT3n = 31aAge (yr)56.95 ± 12.05 57.16 ± 13.71 55.16 ± 8.40 58.52 ± 13.440.66Gender 0.047 female29 (31.18) 10 (32.26) 14 (61.76) 5 (16.13) male64 (68.82) 21 (67.74) 17 (54.84) 26 (83.87)BMI 0.564 Underweight19 (20.43) 8 (25.81) 4 (12.90) 7 (22.58) Normal43 (46.24) 12 (38.71) 14 (45.16) 17 (54.84) Overweight26 (27.96) 10 (32.26) 10 (32.26) 6 (19.35) Obese5 (5.38) 1 (3.23) 3 (9.68) 1 (3.23)History of ALS 0.723 No85 (91.40) 29 (93.55) 29 (93.55) 27 (87.10) Yes8 (8.60) 2 (6.45) 2 (6.45) 4 (12.90)Physical activity 0.239 Sedentary14 (15.05) 4 (12.90) 6 (19.35) 4 (12.90) Low51 (54.84) 12 (38.71) 18 (58.06) 21 (67.74) Moderate20 (21.51) 11 (35.48) 5 (16.13) 4 (12.90) Active8 (8.60) 4 (12.90) 2 (6.45) 2 (6.45)Diagnosis (months)23.90 ± 20.45 19.23 ± 13.86 18.81 ± 10.36 33.68 ± 28.90 0.005 Weight (kg)65.36 ± 13.34 63.80 ± 10.83 68.21 ± 16.02 64.08 ± 12.630.935Weight changes7.40 ± 7.97 8.32 ± 8.20 7.29 ± 8.59 6.58 ± 7.230.392Height (cm) 169.63 ± 8.50169.58 ± 8.84167.71 ± 9.29171.61 ± 7.01 0.349ALSFRS-R41 (37.5, 45)41 (33, 45)43 (40, 46)40 (38, 45)0.658MRC score60 (54, 64.5)60 (50, 64)60 (54, 65)61 (55, 64)0.947Intracellular water (L) 20.52 ± 4.0120.07 ± 3.3220.32 ± 4.7321.16 ± 3.910.286Extracellular water (L) 13.37 ± 2.4213.20 ± 2.1113.21 ± 2.8513.71 ± 2.290.414Soft lean mass (kg) 43.34 ± 8.2442.55 ± 6.9742.84 ± 9.6844.63 ± 7.960.324Fat free mass (kg) 46.07 ± 8.7345.27 ± 7.3745.57 ± 10.3147.37 ± 8.390.346Skeletal muscle mass (kg) 24.84 ± 5.3024.39 ± 4.6224.48 ± 6.1425.64 ± 5.120.357Fat mass (%) 28.53 ± 10.6327.88 ± 12.2132.27 ± 10.2825.43 ± 8.190.367Mid-arm circumference (cm) 26.80 ± 4.0426.53 ± 4.2327.35 ± 3.7226.50 ± 4.220.975DII 0.00 ± 0.85-0.85 ± 0.29-0.13 ± 0.200.99 ± 0.56 < 0.001 Data are expressed as Mean ± Standard deviation, median (IQR), and n (%)Bold values ​​are significant (less than 0.05)aParticipants categorized within the first tertile of the dietary inflammatory index exhibited scores below − 0.42; those in the second tertile demonstrated scores ranging from − 0.42 to 0.21; individuals in the third tertile had scores exceeding 0.21b Derived from ANOVA test, Kruskal-Wallis H test, and χ2 test, as applicable Table 1Study characteristics of ALS patients stratified by tertiles of the dietary inflammatory indexTotalN = 93a Dietary Inflammatory Index P-valuebT1n = 31aT2n = 31aT3n = 31aAge (yr)56.95 ± 12.05 57.16 ± 13.71 55.16 ± 8.40 58.52 ± 13.440.66Gender 0.047 female29 (31.18) 10 (32.26) 14 (61.76) 5 (16.13) male64 (68.82) 21 (67.74) 17 (54.84) 26 (83.87)BMI 0.564 Underweight19 (20.43) 8 (25.81) 4 (12.90) 7 (22.58) Normal43 (46.24) 12 (38.71) 14 (45.16) 17 (54.84) Overweight26 (27.96) 10 (32.26) 10 (32.26) 6 (19.35) Obese5 (5.38) 1 (3.23) 3 (9.68) 1 (3.23)History of ALS 0.723 No85 (91.40) 29 (93.55) 29 (93.55) 27 (87.10) Yes8 (8.60) 2 (6.45) 2 (6.45) 4 (12.90)Physical activity 0.239 Sedentary14 (15.05) 4 (12.90) 6 (19.35) 4 (12.90) Low51 (54.84) 12 (38.71) 18 (58.06) 21 (67.74) Moderate20 (21.51) 11 (35.48) 5 (16.13) 4 (12.90) Active8 (8.60) 4 (12.90) 2 (6.45) 2 (6.45)Diagnosis (months)23.90 ± 20.45 19.23 ± 13.86 18.81 ± 10.36 33.68 ± 28.90 0.005 Weight (kg)65.36 ± 13.34 63.80 ± 10.83 68.21 ± 16.02 64.08 ± 12.630.935Weight changes7.40 ± 7.97 8.32 ± 8.20 7.29 ± 8.59 6.58 ± 7.230.392Height (cm) 169.63 ± 8.50169.58 ± 8.84167.71 ± 9.29171.61 ± 7.01 0.349ALSFRS-R41 (37.5, 45)41 (33, 45)43 (40, 46)40 (38, 45)0.658MRC score60 (54, 64.5)60 (50, 64)60 (54, 65)61 (55, 64)0.947Intracellular water (L) 20.52 ± 4.0120.07 ± 3.3220.32 ± 4.7321.16 ± 3.910.286Extracellular water (L) 13.37 ± 2.4213.20 ± 2.1113.21 ± 2.8513.71 ± 2.290.414Soft lean mass (kg) 43.34 ± 8.2442.55 ± 6.9742.84 ± 9.6844.63 ± 7.960.324Fat free mass (kg) 46.07 ± 8.7345.27 ± 7.3745.57 ± 10.3147.37 ± 8.390.346Skeletal muscle mass (kg) 24.84 ± 5.3024.39 ± 4.6224.48 ± 6.1425.64 ± 5.120.357Fat mass (%) 28.53 ± 10.6327.88 ± 12.2132.27 ± 10.2825.43 ± 8.190.367Mid-arm circumference (cm) 26.80 ± 4.0426.53 ± 4.2327.35 ± 3.7226.50 ± 4.220.975DII 0.00 ± 0.85-0.85 ± 0.29-0.13 ± 0.200.99 ± 0.56 < 0.001 Data are expressed as Mean ± Standard deviation, median (IQR), and n (%)Bold values ​​are significant (less than 0.05)aParticipants categorized within the first tertile of the dietary inflammatory index exhibited scores below − 0.42; those in the second tertile demonstrated scores ranging from − 0.42 to 0.21; individuals in the third tertile had scores exceeding 0.21b Derived from ANOVA test, Kruskal-Wallis H test, and χ2 test, as applicable Study characteristics of ALS patients stratified by tertiles of the dietary inflammatory index Data are expressed as Mean ± Standard deviation, median (IQR), and n (%) Bold values ​​are significant (less than 0.05) aParticipants categorized within the first tertile of the dietary inflammatory index exhibited scores below − 0.42; those in the second tertile demonstrated scores ranging from − 0.42 to 0.21; individuals in the third tertile had scores exceeding 0.21 b Derived from ANOVA test, Kruskal-Wallis H test, and χ2 test, as applicable Table 2Dietary nutrient intake of ALS patients stratified by tertiles of the dietary inflammatory indexTotalN = 93aDietary Inflammatory IndexT1n = 31aT2n = 31aT3n = 31aP-valuebEnergy (kcal/d)3,515.63 ± 818.213,395.23 ± 531.713,657.21 ± 748.183,494.43 ± 1,083.700.636Macronutrients Protein (gm)127.60 ± 30.64122.99 ± 23.95134.55 ± 30.33125.28 ± 36.170.771 Carbohydrate (gm)492.25 ± 148.27465.10 ± 98.28507.22 ± 110.25504.44 ± 210.840.299 Total fat (gm)120.93 ± 29.93122.46 ± 27.42126.78 ± 32.48113.54 ± 29.090.242Micronutrients Vitamin E (mg)11.89 ± 3.6513.18 ± 3.6812.41 ± 3.7710.08 ± 2.80 < 0.001 Vitamin A (µg)1,468.51 ± 1,115.292,203.30 ± 1,530.591,338.41 ± 660.81863.83 ± 286.18 < 0.001 Thiamin (mg)2.27 ± 0.782.39 ± 0.772.30 ± 0.502.12 ± 0.990.185 Riboflavin (mg)2.84 ± 0.772.90 ± 0.852.99 ± 0.612.63 ± 0.810.179 Niacin (mg)80.18 ± 40.4172.14 ± 26.5882.88 ± 27.8785.53 ± 58.500.194 Pantothenic acid8.88 ± 2.158.84 ± 1.939.29 ± 1.968.52 ± 2.510.562 Vitamin B6 (mg)4.36 ± 2.315.55 ± 3.324.13 ± 1.223.41 ± 1.17 < 0.001 Folic acid (µg)375.19 ± 89.78398.57 ± 74.45389.69 ± 91.63337.30 ± 92.27 0.006 Vitamin B12 (µg)5.91 ± 2.435.86 ± 2.936.68 ± 2.365.19 ± 1.670.279 Vitamin C (mg)166.17 ± 64.03197.99 ± 69.15165.47 ± 54.88135.04 ± 52.26 < 0.001 Vitamin D (µg)3.90 ± 5.685.33 ± 9.513.46 ± 1.912.91 ± 1.200.09 Vitamin K (µg)567.68 ± 191.30634.13 ± 183.20632.27 ± 184.14436.64 ± 134.69 < 0.001 Calcium (mg)1,039.33 ± 309.30976.33 ± 248.231,099.04 ± 283.661,042.62 ± 378.810.402 Phosphorus (mg)1,853.32 ± 409.701,801.22 ± 333.701,945.64 ± 331.041,813.08 ± 529.640.91 Magnesium (mg)505.77 ± 136.10497.83 ± 80.55516.40 ± 105.19503.09 ± 197.650.88 Fluoride (µg)1,906.30 ± 1,463.092,041.51 ± 1,445.081,671.62 ± 1,426.882,005.76 ± 1,534.40 0.009 Manganese (mg)8.26 ± 3.557.74 ± 1.898.09 ± 2.238.96 ± 5.410.178 Iron (mg)20.62 ± 6.1620.55 ± 3.6021.41 ± 4.9919.91 ± 8.800.686 Zinc (mg)19.31 ± 5.0618.08 ± 2.9920.47 ± 4.9719.39 ± 6.480.31 Copper (mg)2.90 ± 1.012.87 ± 0.602.96 ± 0.872.89 ± 1.420.94 Sodium (mg)4,729.31 ± 1,310.694,508.00 ± 1,067.495,156.94 ± 1,415.054,522.98 ± 1,357.480.964 Potassium (mg)4,998.81 ± 1,184.195,219.49 ± 904.575,159.01 ± 1,059.974,617.92 ± 1,460.09 0.044 Selenium (µg)142.80 ± 100.15181.70 ± 156.72138.10 ± 49.38108.60 ± 31.06 0.003 Data are expressed as Mean ± Standard deviationBold values ​​are significant (less than 0.05)a Participants categorized within the first tertile of the dietary inflammatory index exhibited scores below − 0.42; those in the second tertile demonstrated scores ranging from − 0.42 to 0.21; individuals in the third tertile had scores exceeding 0.21b All values were statistically adjusted for gender, age and energy, with the exception of energy intake, which was adjusted solely for gender and age through the application of Analysis of Covariance (ANCOVA) Table 2Dietary nutrient intake of ALS patients stratified by tertiles of the dietary inflammatory indexTotalN = 93aDietary Inflammatory IndexT1n = 31aT2n = 31aT3n = 31aP-valuebEnergy (kcal/d)3,515.63 ± 818.213,395.23 ± 531.713,657.21 ± 748.183,494.43 ± 1,083.700.636Macronutrients Protein (gm)127.60 ± 30.64122.99 ± 23.95134.55 ± 30.33125.28 ± 36.170.771 Carbohydrate (gm)492.25 ± 148.27465.10 ± 98.28507.22 ± 110.25504.44 ± 210.840.299 Total fat (gm)120.93 ± 29.93122.46 ± 27.42126.78 ± 32.48113.54 ± 29.090.242Micronutrients Vitamin E (mg)11.89 ± 3.6513.18 ± 3.6812.41 ± 3.7710.08 ± 2.80 < 0.001 Vitamin A (µg)1,468.51 ± 1,115.292,203.30 ± 1,530.591,338.41 ± 660.81863.83 ± 286.18 < 0.001 Thiamin (mg)2.27 ± 0.782.39 ± 0.772.30 ± 0.502.12 ± 0.990.185 Riboflavin (mg)2.84 ± 0.772.90 ± 0.852.99 ± 0.612.63 ± 0.810.179 Niacin (mg)80.18 ± 40.4172.14 ± 26.5882.88 ± 27.8785.53 ± 58.500.194 Pantothenic acid8.88 ± 2.158.84 ± 1.939.29 ± 1.968.52 ± 2.510.562 Vitamin B6 (mg)4.36 ± 2.315.55 ± 3.324.13 ± 1.223.41 ± 1.17 < 0.001 Folic acid (µg)375.19 ± 89.78398.57 ± 74.45389.69 ± 91.63337.30 ± 92.27 0.006 Vitamin B12 (µg)5.91 ± 2.435.86 ± 2.936.68 ± 2.365.19 ± 1.670.279 Vitamin C (mg)166.17 ± 64.03197.99 ± 69.15165.47 ± 54.88135.04 ± 52.26 < 0.001 Vitamin D (µg)3.90 ± 5.685.33 ± 9.513.46 ± 1.912.91 ± 1.200.09 Vitamin K (µg)567.68 ± 191.30634.13 ± 183.20632.27 ± 184.14436.64 ± 134.69 < 0.001 Calcium (mg)1,039.33 ± 309.30976.33 ± 248.231,099.04 ± 283.661,042.62 ± 378.810.402 Phosphorus (mg)1,853.32 ± 409.701,801.22 ± 333.701,945.64 ± 331.041,813.08 ± 529.640.91 Magnesium (mg)505.77 ± 136.10497.83 ± 80.55516.40 ± 105.19503.09 ± 197.650.88 Fluoride (µg)1,906.30 ± 1,463.092,041.51 ± 1,445.081,671.62 ± 1,426.882,005.76 ± 1,534.40 0.009 Manganese (mg)8.26 ± 3.557.74 ± 1.898.09 ± 2.238.96 ± 5.410.178 Iron (mg)20.62 ± 6.1620.55 ± 3.6021.41 ± 4.9919.91 ± 8.800.686 Zinc (mg)19.31 ± 5.0618.08 ± 2.9920.47 ± 4.9719.39 ± 6.480.31 Copper (mg)2.90 ± 1.012.87 ± 0.602.96 ± 0.872.89 ± 1.420.94 Sodium (mg)4,729.31 ± 1,310.694,508.00 ± 1,067.495,156.94 ± 1,415.054,522.98 ± 1,357.480.964 Potassium (mg)4,998.81 ± 1,184.195,219.49 ± 904.575,159.01 ± 1,059.974,617.92 ± 1,460.09 0.044 Selenium (µg)142.80 ± 100.15181.70 ± 156.72138.10 ± 49.38108.60 ± 31.06 0.003 Data are expressed as Mean ± Standard deviationBold values ​​are significant (less than 0.05)a Participants categorized within the first tertile of the dietary inflammatory index exhibited scores below − 0.42; those in the second tertile demonstrated scores ranging from − 0.42 to 0.21; individuals in the third tertile had scores exceeding 0.21b All values were statistically adjusted for gender, age and energy, with the exception of energy intake, which was adjusted solely for gender and age through the application of Analysis of Covariance (ANCOVA) Dietary nutrient intake of ALS patients stratified by tertiles of the dietary inflammatory index Data are expressed as Mean ± Standard deviation Bold values ​​are significant (less than 0.05) a Participants categorized within the first tertile of the dietary inflammatory index exhibited scores below − 0.42; those in the second tertile demonstrated scores ranging from − 0.42 to 0.21; individuals in the third tertile had scores exceeding 0.21 b All values were statistically adjusted for gender, age and energy, with the exception of energy intake, which was adjusted solely for gender and age through the application of Analysis of Covariance (ANCOVA) Link of DII with ALSFRS-R, MRC score, and DPR As depicted in Table 3, the association between the DII and key clinical outcomes, encompassing ALSFRS-R, MRC score, and DPR, revealed variable relationships across models and tertiles of DII. For ALSFRS-R, Model 4 demonstrated an insignificant result. For the MRC score, Model 4 exhibited a non-significant association. In contrast, DPR displayed a significant negative association with the third tertile (T3) of DII (β T3 vs. T1= -1.1, 95CI%: -2.2, -0.04; Ptrend= 0.04). The box plots visualized the link between DII with ALSFRS-R, MRC, and DPR among patients with ALS (Fig. 1A and C, respectively). A negative correlation between DII and DPR was observed using Spearman’s correlation (ρ=-0.313, P < 0.001) (Fig. 2A and C). Table 3Association of the dietary inflammatory index with the ALSFRS-R, MRC score, and DPR among ALS patientsDietary Inflammatory Index*P-valueContinuousβP-valueT1n = 31βT2n = 31β (95% CI)P-valueT3n = 31β (95% CI)P-valueASLFRS-Ra Model 10.90 (-1.0, 2.9)0.4Ref.-0.84 (-4.9, 3.2)0.70.90 (-3.2, 5.0)0.70.65 Model 20.84 (-1.1, 2.8)0.4Ref.-0.70 (-4.8, 3.4)0.70.81 (-3.3, 4.9)0.70.71 Model 30.81 (-1.1, 2.7)0.4Ref.-1.4 (-5.4, 2.7)0.51.1 (-2.9, 5.1)0.60.59 Model 41.3 (-0.47, 3.1)0.14Ref.-0.03 (-3.7, 3.7)> 0.92.8 (-1.0, 6.7)0.150.15MRC score b Model 10.85 (-2.0, 3.7)0.5Ref.-2.8 (-8.6, 3.0)0.3-0.19 (-6.0, 5.6)> 0.90.94 Model 21.1 (-1.8, 3.9)0.5Ref.-3.1 (-9.0, 2.7)0.30.33 (-5.6, 6.2)> 0.90.94 Model 31.1 (-1.7, 3.9)0.4Ref.-3.7 (-9.6, 2.2)0.20.79 (-5.0, 6.6)0.80.82 Model 40.96 (-1.6, 3.5)0.5Ref.-2.9 (-8.1, 2.3)0.30.11 (-5.3, 5.6)> 0.90.98DPR c Model 1-0.48 (-1.0, 0.03)0.067Ref.-0.57 (-1.6, 0.50)0.3-1.1 (-2.2, 0.00) 0.05 0.04 Model 2-0.47 (-1.0, 0.06)0.079Ref.-0.58 (-1.7, 0.51)0.3-1.0 (-2.1, 0.05)0.061 0.05 Model 3-0.45 (-0.96, 0.06)0.081Ref.-0.43 (-1.5, 0.63)0.4-1.0 (-2.1, 0.01) 0.05 0.05 Model 4-0.49 (-1.0, 0.03)0.067Ref.-0.61 (-1.7, 0.47)0.3-1.1 (-2.2, -0.04) 0.04 0.04 Bold values ​​are significant (less than 0.05)Abbreviations: ALSFRS-R Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised, MRC Medical Research Council score, DPR Disease Progression Rate, BMI body mass index* Multiple linear regression analysis was used to derive β coefficients and their corresponding 95% CIs. The overarching trend of the β across ascending tertiles was investigated by regarding the median score within each tertiles as a continuous predictor variableaModel 1: crude model; Model 2: adjusted for gender and age; Model 3: additional adjustments were applied for BMI; Model 4: additional adjustments were applied for physical activty, history of ALS, and disease durationbModel 1: crude model; Model 2: adjusted for gender and age; Model 3: additional adjustments were applied for BMI; Model 4: additional adjustments were applied for physical activty, history of ALS, disease duration, and DPRcModel 1: crude model; Model 2: adjusted for gender and age; Model 3: additional adjustments were applied for BMI; Model 4: additional adjustments were applied for physical activty, and history of ALS Table 3Association of the dietary inflammatory index with the ALSFRS-R, MRC score, and DPR among ALS patientsDietary Inflammatory Index*P-valueContinuousβP-valueT1n = 31βT2n = 31β (95% CI)P-valueT3n = 31β (95% CI)P-valueASLFRS-Ra Model 10.90 (-1.0, 2.9)0.4Ref.-0.84 (-4.9, 3.2)0.70.90 (-3.2, 5.0)0.70.65 Model 20.84 (-1.1, 2.8)0.4Ref.-0.70 (-4.8, 3.4)0.70.81 (-3.3, 4.9)0.70.71 Model 30.81 (-1.1, 2.7)0.4Ref.-1.4 (-5.4, 2.7)0.51.1 (-2.9, 5.1)0.60.59 Model 41.3 (-0.47, 3.1)0.14Ref.-0.03 (-3.7, 3.7)> 0.92.8 (-1.0, 6.7)0.150.15MRC score b Model 10.85 (-2.0, 3.7)0.5Ref.-2.8 (-8.6, 3.0)0.3-0.19 (-6.0, 5.6)> 0.90.94 Model 21.1 (-1.8, 3.9)0.5Ref.-3.1 (-9.0, 2.7)0.30.33 (-5.6, 6.2)> 0.90.94 Model 31.1 (-1.7, 3.9)0.4Ref.-3.7 (-9.6, 2.2)0.20.79 (-5.0, 6.6)0.80.82 Model 40.96 (-1.6, 3.5)0.5Ref.-2.9 (-8.1, 2.3)0.30.11 (-5.3, 5.6)> 0.90.98DPR c Model 1-0.48 (-1.0, 0.03)0.067Ref.-0.57 (-1.6, 0.50)0.3-1.1 (-2.2, 0.00) 0.05 0.04 Model 2-0.47 (-1.0, 0.06)0.079Ref.-0.58 (-1.7, 0.51)0.3-1.0 (-2.1, 0.05)0.061 0.05 Model 3-0.45 (-0.96, 0.06)0.081Ref.-0.43 (-1.5, 0.63)0.4-1.0 (-2.1, 0.01) 0.05 0.05 Model 4-0.49 (-1.0, 0.03)0.067Ref.-0.61 (-1.7, 0.47)0.3-1.1 (-2.2, -0.04) 0.04 0.04 Bold values ​​are significant (less than 0.05)Abbreviations: ALSFRS-R Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised, MRC Medical Research Council score, DPR Disease Progression Rate, BMI body mass index* Multiple linear regression analysis was used to derive β coefficients and their corresponding 95% CIs. The overarching trend of the β across ascending tertiles was investigated by regarding the median score within each tertiles as a continuous predictor variableaModel 1: crude model; Model 2: adjusted for gender and age; Model 3: additional adjustments were applied for BMI; Model 4: additional adjustments were applied for physical activty, history of ALS, and disease durationbModel 1: crude model; Model 2: adjusted for gender and age; Model 3: additional adjustments were applied for BMI; Model 4: additional adjustments were applied for physical activty, history of ALS, disease duration, and DPRcModel 1: crude model; Model 2: adjusted for gender and age; Model 3: additional adjustments were applied for BMI; Model 4: additional adjustments were applied for physical activty, and history of ALS Association of the dietary inflammatory index with the ALSFRS-R, MRC score, and DPR among ALS patients Bold values ​​are significant (less than 0.05) Abbreviations: ALSFRS-R Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised, MRC Medical Research Council score, DPR Disease Progression Rate, BMI body mass index * Multiple linear regression analysis was used to derive β coefficients and their corresponding 95% CIs. The overarching trend of the β across ascending tertiles was investigated by regarding the median score within each tertiles as a continuous predictor variable aModel 1: crude model; Model 2: adjusted for gender and age; Model 3: additional adjustments were applied for BMI; Model 4: additional adjustments were applied for physical activty, history of ALS, and disease duration bModel 1: crude model; Model 2: adjusted for gender and age; Model 3: additional adjustments were applied for BMI; Model 4: additional adjustments were applied for physical activty, history of ALS, disease duration, and DPR cModel 1: crude model; Model 2: adjusted for gender and age; Model 3: additional adjustments were applied for BMI; Model 4: additional adjustments were applied for physical activty, and history of ALS Fig. 1Box plot of the association between DII with ALSFRS-R (A), MRC score (B), and DPR (C) in individuals with ALS Box plot of the association between DII with ALSFRS-R (A), MRC score (B), and DPR (C) in individuals with ALS Fig. 2Spearman’s correlations of DII with ALSFRS-R (A), MRC score (B), and DPR (C) in participants with ALS Spearman’s correlations of DII with ALSFRS-R (A), MRC score (B), and DPR (C) in participants with ALS Link of DII with MAC and body composition As illustrated in Table 4, after adjusting for potential confounders, the association of DII tertiles with MAC and body composition was not significant. The box plots visualized the link between DII with body composition in individuals with ALS (Fig. 3A and I, respectively). Positive correlations of DII with SLM (r = 0.203, P = 0.033), FFM (r = 0.200, P = 0.035), SMM (r = 0.198, P = 0.037), ICW (r = 0.203, P = 0.033), and ECW (r = 0.190, P = 0.046) were observed using Pearson’s correlation (Fig. 4A and I). Table 4Association between the dietary inflammatory index and components of body composition among ALS patientsDietary Inflammatory Index*P-trendContinuousβP-valueT1n = 31βT2n = 31β (95% CI)P-valueT3n = 31β (95% CI)P-valueWeight a Model 11.3 (-1.9, 4.6)0.4Ref.4.4 (-2.3, 11)0.20.28 (-6.4, 7.0)> 0.90.93 Model 21.0 (-2.3, 4.3)0.5Ref.5.2 (-1.5, 12)0.13-0.70 (-7.4, 6.0)0.80.88 Model 30.86 (-2.6, 4.3)0.6Ref.5.1 (-1.9, 12)0.2-0.95 (-8.1, 6.2)0.80.80 Model 40.41 (-3.0, 3.8)0.8Ref.3.5 (-3.4, 10)0.3-2.3 (-9.5, 4.9)0.50.57Weight change a Model 1-0.55 (-2.5, 1.4)0.6Ref.-1.0 (-5.1, 3.0)0.6-1.7 (-5.8, 2.3)0.40.39 Model 2-0.51 (-2.5, 1.5)0.6Ref.-1.0 (-5.1, 3.1)0.6-1.6 (-5.8, 2.5)0.40.42 Model 3-0.52 (-2.5, 1.5)0.6Ref.-1.6 (-5.8, 2.6)0.4-1.9 (-6.2, 2.3)0.40.36 Model 4-0.68 (-2.7, 1.3)0.5Ref.-0.74 (-4.8, 3.3)0.7-2.4 (-6.7, 1.8)0.30.26BMI a Model 10.13 (-1.0, 1.3)0.8Ref.1.8 (-0.56, 4.2)0.13-0.57 (-3.0, 1.8)0.60.25 Model 20.24 (-0.94, 1.4)0.7Ref.1.7 (-0.73, 4.1)0.2-0.42 (-2.8, 2.0)0.70.33 Model 30.12 (-1.1, 1.3)0.8Ref.1.6 (-0.84, 4.1)0.2-0.61 (-3.1, 1.9)0.60.42 Model 40.00 (-1.2, 1.2)> 0.9Ref.1.1 (-1.4, 3.5)0.4-1.0 (-3.6, 1.5)0.40.26FFM b Model 11.4 (-0.77, 3.5)0.2Ref.0.30 (-4.1, 4.7)0.92.1 (-2.3, 6.5)0.60.34 Model 20.68 (-1.2, 2.6)0.5Ref.1.5 (-2.5, 5.4)0.50.60 (-3.4, 4.6)0.80.74 Model 30.54 (-1.1, 2.2)0.5Ref.0.32 (-3.2, 3.8)0.90.98 (-2.5, 4.4)0.60.57 Model 40.80 (-0.91, 2.5)0.4Ref.0.30 (-3.2, 3.8)0.91.4 (-2.3, 5.1)0.50.46SLM b Model 11.3 (-0.72, 3.3)0.2Ref.0.29 (-3.9, 4.5)0.92.1 (-2.1, 6.3)0.30.32 Model 20.63 (-1.2, 2.4)0.5Ref.1.4 (-2.3, 5.1)0.40.64 (-3.1, 4.4)0.70.71 Model 30.50 (-1.1, 2.1)0.5Ref.0.34 (-3.0, 3.6)0.80.98 (-2.3, 4.3)0.60.55 Model 40.75 (-0.87, 2.4)0.4Ref.0.35 (-3.0, 3.7)0.81.4 (-2.1, 4.9)0.40.43FM b Model 1-0.44 (-3.0, 2.2)0.7Ref.4.4 (-0.83, 9.6)0.10-2.5 (-7.7, 2.8)0.40.47 Model 20.26 (-2.2, 2.7)0.8Ref.3.3 (-1.6, 8.3)0.2-1.1 (-6.1, 3.8)0.70.66 Model 30.01 (-1.9, 1.9)> 0.9Ref.1.5 (-2.4, 5.5)0.4-0.79 (-4.7, 3.1)0.70.68 Model 4-0.67 (-2.6, 1.3)0.5Ref.0.87 (-3.1, 4.9)0.7-2.1 (-6.3, 2.1)0.30.33SMM b Model 10.81 (-0.48, 2.1)0.2Ref.0.10 (-2.6, 2.8)> 0.91.2 (-1.4, 3.9)0.40.35 Model 20.41 (-0.76, 1.6)0.5Ref.0.81 (-1.6, 3.2)0.50.36 (-2.1, 2.8)0.80.75 Model 30.34 (-0.69, 1.4)0.5Ref.0.13 (-2.0, 2.3)> 0.90.61 (-1.5, 2.8)0.60.57 Model 40.48 (-0.59, 1.6)0.4Ref.0.16 (-2.0, 2.4)0.90.81 (-1.5, 3.1)0.50.49MAC 2 Model 10.09 (-0.90, 1.1)0.9Ref.0.82 (-1.2, 2.9)0.4-0.03 (-2.1, 2.0)> 0.90.97 Model 20.26 (-0.71, 1.2)0.6Ref.0.50 (-1.5, 2.5)0.60.29 (-1.7, 2.3)0.80.76 Model 30.22 (-0.68, 1.1)0.6Ref.0.08 (-1.8, 2.0)> 0.90.45 (-1.4, 2.3)0.60.63 Model 40.14 (-0.83, 1.1)0.8Ref.-0.07 (-2.1, 1.9)> 0.90.38 (-1.7, 2.5)0.70.72ICW b Model 10.63 (-0.34, 1.6)0.2Ref.0.25 (-1.8, 2.3)0.81.1 (-0.94, 3.1)0.30.28 Model 20.33 (-0.56, 1.2)0.5Ref.0.79 (-1.0, 2.6)0.40.43 (-1.4, 2.3)0.60.62 Model 30.26 (-0.52, 1.0)0.5Ref.0.26 (-1.4, 1.9)0.80.59 (-1.0, 2.2)0.50.47 Model 40.36 (-0.45, 1.2)0.4Ref.0.26 (-1.4, 1.9)0.80.73 (1.0, 2.5)0.40.41ECW b Model 10.33 (-0.26, 0.92)0.3Ref.0.01 (-1.2, 1.2)> 0.90.51 (-0.72, 1.7)0.40.41 Model 20.12 (-0.39, 0.64)0.6Ref.0.35 (-0.71, 1.4)0.50.05 (-1.0, 1.1)> 0.90.91 Model 30.08 (-0.37, 0.53)0.7Ref.0.02 (-0.91, 0.96)> 0.90.14 (-0.78, 1.1)0.80.75 Model 40.18 (-0.27, 0.63)0.4Ref.0.04 (-0.88, 0.97)> 0.90.34 (-0.62, 1.3)0.50.48Abbreviations: BMI body mass index, FFM fat free mass, FM fat mass, SLM soft lean mass, SMM skeletal muscle mass, MAC mid-arm circumference, ICW intracellular water, ECW extracellular water* Multiple linear regression analysis was used to derive β coefficients and their corresponding 95% CIs. The overarching trend of the β across ascending tertiles was investigated by regarding the median score within each tertiles as a continuous predictor variableaModel 1: crude model; Model 2: adjusted for gender and age; Model 3: additional adjustments were applied for physical activty; Model 4: additional adjustments were applied for history of ALS, disease duration, and DPRbModel 1: crude model; Model 2: adjusted for gender and age; Model 3: additional adjustments were applied for BMI; Model 4: additional adjustments were applied for physical activty, history of ALS, disease duration, and DPR Table 4Association between the dietary inflammatory index and components of body composition among ALS patientsDietary Inflammatory Index*P-trendContinuousβP-valueT1n = 31βT2n = 31β (95% CI)P-valueT3n = 31β (95% CI)P-valueWeight a Model 11.3 (-1.9, 4.6)0.4Ref.4.4 (-2.3, 11)0.20.28 (-6.4, 7.0)> 0.90.93 Model 21.0 (-2.3, 4.3)0.5Ref.5.2 (-1.5, 12)0.13-0.70 (-7.4, 6.0)0.80.88 Model 30.86 (-2.6, 4.3)0.6Ref.5.1 (-1.9, 12)0.2-0.95 (-8.1, 6.2)0.80.80 Model 40.41 (-3.0, 3.8)0.8Ref.3.5 (-3.4, 10)0.3-2.3 (-9.5, 4.9)0.50.57Weight change a Model 1-0.55 (-2.5, 1.4)0.6Ref.-1.0 (-5.1, 3.0)0.6-1.7 (-5.8, 2.3)0.40.39 Model 2-0.51 (-2.5, 1.5)0.6Ref.-1.0 (-5.1, 3.1)0.6-1.6 (-5.8, 2.5)0.40.42 Model 3-0.52 (-2.5, 1.5)0.6Ref.-1.6 (-5.8, 2.6)0.4-1.9 (-6.2, 2.3)0.40.36 Model 4-0.68 (-2.7, 1.3)0.5Ref.-0.74 (-4.8, 3.3)0.7-2.4 (-6.7, 1.8)0.30.26BMI a Model 10.13 (-1.0, 1.3)0.8Ref.1.8 (-0.56, 4.2)0.13-0.57 (-3.0, 1.8)0.60.25 Model 20.24 (-0.94, 1.4)0.7Ref.1.7 (-0.73, 4.1)0.2-0.42 (-2.8, 2.0)0.70.33 Model 30.12 (-1.1, 1.3)0.8Ref.1.6 (-0.84, 4.1)0.2-0.61 (-3.1, 1.9)0.60.42 Model 40.00 (-1.2, 1.2)> 0.9Ref.1.1 (-1.4, 3.5)0.4-1.0 (-3.6, 1.5)0.40.26FFM b Model 11.4 (-0.77, 3.5)0.2Ref.0.30 (-4.1, 4.7)0.92.1 (-2.3, 6.5)0.60.34 Model 20.68 (-1.2, 2.6)0.5Ref.1.5 (-2.5, 5.4)0.50.60 (-3.4, 4.6)0.80.74 Model 30.54 (-1.1, 2.2)0.5Ref.0.32 (-3.2, 3.8)0.90.98 (-2.5, 4.4)0.60.57 Model 40.80 (-0.91, 2.5)0.4Ref.0.30 (-3.2, 3.8)0.91.4 (-2.3, 5.1)0.50.46SLM b Model 11.3 (-0.72, 3.3)0.2Ref.0.29 (-3.9, 4.5)0.92.1 (-2.1, 6.3)0.30.32 Model 20.63 (-1.2, 2.4)0.5Ref.1.4 (-2.3, 5.1)0.40.64 (-3.1, 4.4)0.70.71 Model 30.50 (-1.1, 2.1)0.5Ref.0.34 (-3.0, 3.6)0.80.98 (-2.3, 4.3)0.60.55 Model 40.75 (-0.87, 2.4)0.4Ref.0.35 (-3.0, 3.7)0.81.4 (-2.1, 4.9)0.40.43FM b Model 1-0.44 (-3.0, 2.2)0.7Ref.4.4 (-0.83, 9.6)0.10-2.5 (-7.7, 2.8)0.40.47 Model 20.26 (-2.2, 2.7)0.8Ref.3.3 (-1.6, 8.3)0.2-1.1 (-6.1, 3.8)0.70.66 Model 30.01 (-1.9, 1.9)> 0.9Ref.1.5 (-2.4, 5.5)0.4-0.79 (-4.7, 3.1)0.70.68 Model 4-0.67 (-2.6, 1.3)0.5Ref.0.87 (-3.1, 4.9)0.7-2.1 (-6.3, 2.1)0.30.33SMM b Model 10.81 (-0.48, 2.1)0.2Ref.0.10 (-2.6, 2.8)> 0.91.2 (-1.4, 3.9)0.40.35 Model 20.41 (-0.76, 1.6)0.5Ref.0.81 (-1.6, 3.2)0.50.36 (-2.1, 2.8)0.80.75 Model 30.34 (-0.69, 1.4)0.5Ref.0.13 (-2.0, 2.3)> 0.90.61 (-1.5, 2.8)0.60.57 Model 40.48 (-0.59, 1.6)0.4Ref.0.16 (-2.0, 2.4)0.90.81 (-1.5, 3.1)0.50.49MAC 2 Model 10.09 (-0.90, 1.1)0.9Ref.0.82 (-1.2, 2.9)0.4-0.03 (-2.1, 2.0)> 0.90.97 Model 20.26 (-0.71, 1.2)0.6Ref.0.50 (-1.5, 2.5)0.60.29 (-1.7, 2.3)0.80.76 Model 30.22 (-0.68, 1.1)0.6Ref.0.08 (-1.8, 2.0)> 0.90.45 (-1.4, 2.3)0.60.63 Model 40.14 (-0.83, 1.1)0.8Ref.-0.07 (-2.1, 1.9)> 0.90.38 (-1.7, 2.5)0.70.72ICW b Model 10.63 (-0.34, 1.6)0.2Ref.0.25 (-1.8, 2.3)0.81.1 (-0.94, 3.1)0.30.28 Model 20.33 (-0.56, 1.2)0.5Ref.0.79 (-1.0, 2.6)0.40.43 (-1.4, 2.3)0.60.62 Model 30.26 (-0.52, 1.0)0.5Ref.0.26 (-1.4, 1.9)0.80.59 (-1.0, 2.2)0.50.47 Model 40.36 (-0.45, 1.2)0.4Ref.0.26 (-1.4, 1.9)0.80.73 (1.0, 2.5)0.40.41ECW b Model 10.33 (-0.26, 0.92)0.3Ref.0.01 (-1.2, 1.2)> 0.90.51 (-0.72, 1.7)0.40.41 Model 20.12 (-0.39, 0.64)0.6Ref.0.35 (-0.71, 1.4)0.50.05 (-1.0, 1.1)> 0.90.91 Model 30.08 (-0.37, 0.53)0.7Ref.0.02 (-0.91, 0.96)> 0.90.14 (-0.78, 1.1)0.80.75 Model 40.18 (-0.27, 0.63)0.4Ref.0.04 (-0.88, 0.97)> 0.90.34 (-0.62, 1.3)0.50.48Abbreviations: BMI body mass index, FFM fat free mass, FM fat mass, SLM soft lean mass, SMM skeletal muscle mass, MAC mid-arm circumference, ICW intracellular water, ECW extracellular water* Multiple linear regression analysis was used to derive β coefficients and their corresponding 95% CIs. The overarching trend of the β across ascending tertiles was investigated by regarding the median score within each tertiles as a continuous predictor variableaModel 1: crude model; Model 2: adjusted for gender and age; Model 3: additional adjustments were applied for physical activty; Model 4: additional adjustments were applied for history of ALS, disease duration, and DPRbModel 1: crude model; Model 2: adjusted for gender and age; Model 3: additional adjustments were applied for BMI; Model 4: additional adjustments were applied for physical activty, history of ALS, disease duration, and DPR Association between the dietary inflammatory index and components of body composition among ALS patients Abbreviations: BMI body mass index, FFM fat free mass, FM fat mass, SLM soft lean mass, SMM skeletal muscle mass, MAC mid-arm circumference, ICW intracellular water, ECW extracellular water * Multiple linear regression analysis was used to derive β coefficients and their corresponding 95% CIs. The overarching trend of the β across ascending tertiles was investigated by regarding the median score within each tertiles as a continuous predictor variable aModel 1: crude model; Model 2: adjusted for gender and age; Model 3: additional adjustments were applied for physical activty; Model 4: additional adjustments were applied for history of ALS, disease duration, and DPR bModel 1: crude model; Model 2: adjusted for gender and age; Model 3: additional adjustments were applied for BMI; Model 4: additional adjustments were applied for physical activty, history of ALS, disease duration, and DPR Fig. 3Box plot of the association between DII with weight (A), weight change (B), Soft Lean Mass (C), Fat Free Mass (D), Skeletal Muscle Mass (E), Fat Mass (F), Mid-arm Circumference (G), Intracellular Water (H), and Extracellular Water (I) in individuals with ALS Box plot of the association between DII with weight (A), weight change (B), Soft Lean Mass (C), Fat Free Mass (D), Skeletal Muscle Mass (E), Fat Mass (F), Mid-arm Circumference (G), Intracellular Water (H), and Extracellular Water (I) in individuals with ALS Fig. 4Pearson’s correlations of DII with weight (A), weight changes (B), BMI (C), SLM (D), FFM (E), SMM (F), FM (G), MAC (H), ICW (I), and ECW (J) in adults with ALS Pearson’s correlations of DII with weight (A), weight changes (B), BMI (C), SLM (D), FFM (E), SMM (F), FM (G), MAC (H), ICW (I), and ECW (J) in adults with ALS Subgroup analyses As presented in Supplementary Table 2, subgroup analyses were conducted considering age, gender, BMI, physical activity, history of ALS, and DPR among patients with ALS, adjusting for potential confounders in Model 4. A significant positive association was identified between the T3 of the DII and the ALSFRS-R in individuals with vigorous (P < 0.001) moderate (P < 0.001) physical activity compared to those with light physical activity. Similarly, for MRC scores, significant positive associations were detected for patients with vigorous (P = 0.010) physical activity compared to those with light physical activity. Underweight patients exhibited a non-inverse relationship between the T3 of DII and DPR (P = 0.002) compared to normal weight. Furthermore, individuals with vigorous physical activity showed an inverse association between the T3 of DII and DPR compared to those with light physical activity (P = 0.031). Regarding ICW and ECW, males exhibited a significantly higher association with the T3 of DII compared to females (P < 0.001). Moreover, overweight and obese individuals illustrated positive associations with the T3 of DII compared to normal-weight individuals (ICW: P = 0.003, P < 0.001; ECW: ICW: P = 0.001, P < 0.001, respectively). Patients with slow (P = 0.012) and intermediate (P = 0.003) DPR displayed a positive association between the T3 of DII and weight compared to those with fast DPR. Furthermore, a negative association between the T3 of DII and weight change was observed in patients with a slow DPR (P = 0.030). ALS patients with slow and intermediate DPR demonstrated a positive association between the T3 of DII and BMI compared to those with fast DPR (P = 0.004; 0.036, respectively). Male individuals exhibited a higher positive association between the T3 of DII and FFM compared to females (P < 0.001). Overweight and obese individuals exhibited a higher positive link with SLM in the T3 of DII compared to normal-weight patients (P < 0.001; 0.002, respectively). Additionally, a SMM was significantly linked to male patients compared to females in the T3 of DII (P < 0.001). Obese and overweight ALS patients in the T3 of DII had higher SMM compared to normal-weight patients (P < 0.001; 0.002, respectively). Regarding FM, males demonstrated significantly lower FM levels in the T3 of DII than females (P < 0.001). Obese (P = 0.006) and overweight (P = 0.032) ALS patients showed a significant positive association between the T3 of DII and FM, whereas underweight patients exhibited a significant negative association (P < 0.001). For MAC, males had significantly lower values than females in T3 of DII (P = 0.035), and underweight individuals in the T3 of DII indicated a negative association compared to those with normal BMI (P = 0.044). Discussion This study is the first to examine the relationship between the DII and ALS progression. Results showed that DII inversely correlates with the DPR but not with other indicators like MRC, ALSFRS, or anthropometric measures. A β coefficient of − 1.1 for the highest versus lowest tertile of DII indicates that patients in T3 experienced, on average, a 1.1-unit lower DPR compared with those in T1. Clinically, this corresponds to a markedly slower rate of functional deterioration, potentially reducing or even offsetting the expected ALSFRS-R decline in typical patients. In underweight patients, DII is positively linked to DPR, while in active individuals, it has an inverse relationship. DII also correlates with various body composition markers, including weight, BMI, and FFM, particularly in overweight, obese, and male patients. Various studies have been conducted on dietary intake and the incidence and progression of ALS, but no definitive results have been obtained. However, it has been shown that metabolic abnormality in glucose and lipid profile level may be associated with disease progression and, contrary to what is thought, are associated with longer survival in these patients, which may indicate higher dietary intake and efforts to combat malnutrition and cachexia in these patients [37]. Among potential dietary risk factors, high intake of glutamate has been shown to be associated with a higher risk of developing ALS [38, 39]. On the other hand, high intake of antioxidants such as vitamin E, carotenoids, and omega-3 fats has been associated with a lower risk of developing ALS [40–42]. In a retrospective study that examined 148 ALS patients, it was shown that protein, fat, and meat intake were associated with increased survival [43]. A case-control study of 212 cases and 212 controls showed that consumption of coffee, tea, whole bread, raw vegetables and citrus fruits was associated with increased ALSFRS score and FVC%, while consumption of red and processed meat, animal proteins, sodium, zinc and glutamic acid were associated with higher risk [38]. Another cross-sectional study of 302 patients showed that higher intake of antioxidants and carotenoids was associated with higher ALSFRS score and FVC% [44]. Another study of 193 patients showed that patients with lower ALSFRS scores consumed fewer nuts, vegetables, cereals, meat and oils but more fruits and beans [45]. Foods that are high in calorie and protein density, such as meats, high-fat dairy products, fried foods such as chicken and French fries, and sweetened beverages and snacks, are classified as pro-inflammatory foods with a high DII [46]. On the other hand, foods such as fruits and vegetables, seeds and nuts, and plant proteins that are lower in fat and higher in fiber and therefore have a lower calorie density are classified as anti-inflammatory foods with a lower DII [46]. Since in ALS, in addition to weight loss resulting from the breakdown of fat and lean body mass, there is a decrease in the function of the muscles involved in swallowing and breathing, dietary recommendations are based on increasing the intake of high-quality proteins, such as animal protein sources such as various meats, dairy products, and eggs [47]. Animal protein sources have high DII because they are accompanied by saturated and trans fats, and therefore it is not far from being expected that in patients who use these types of foods to provide more protein and calories, an inverse relationship between DII and DPR is seen. Whereas in underweight patients, because their overall food intake is lower, DII is directly related DPR, so in these individuals, while controlling inflammation, which is the main factor in the occurrence and progression of the disease, the next step should be to increase protein and calorie intake to see a positive effect in reducing disease progression. An important point in this study is that the relationship between DII and disease progression was measured, not with its incidence and not a cause-and-effect relationship. Therefore, it should be noted that a balanced diet with low DII can be effective in prevention, but when the diagnosis of the disease is confirmed, to reduce the progression of the disease, according to the patient’s and muscle condition and other anthropometric indicators, while controlling DII, a diet that can be effective in reducing inflammation in these patients, high calorie and protein intake is important to prevent muscle breakdown involved in vital processes such as breathing and swallowing. Also, when the disease has progressed to the point that swallowing is impaired, the use of puddings and soft and pureed foods that provide high levels of protein and calorie in a low volume is preferable. Therefore, the results of the present study can partially explain the fact that patients with metabolic abnormality in lipid and glucose have a higher survival rate. Strengths and limitations This study had several strengths which are as follows: (1) Using RStudio and R software for analyzing data and preparing figures; (2) Performing subgroup analyses based age, gender, BMI, physical activity, history of ALS, and DPR among patients with ALS to provide a deeper dive into our data, allowing us to identify differences between specific groups that might otherwise be overlooked; (3) A validated and reliable 153-items dish-based semi-quantitative FFQ, which made responding easy for ALS patients. Its weaknesses include the small sample size, which is due to the rarity of the disease and its low prevalence in the community, as well as the poor prognosis of the patients. Additionally, this sample size restricts statistical power, particularly when conducting multiple adjusted regression models and subgroup analyses. Thus, the confidence intervals in some subgroup analyses are wide, and these findings should be interpreted with caution as exploratory and hypothesis-generating rather than definitive. These stratified results require validation in larger, multi-center cohorts to ensure stability and reproducibility. Moreover, not all patients participating in this study were newly diagnosed and different times had passed since the initial diagnosis of the disease, so the severity of the disease was not the same in all and in this regard there was heterogeneity. To reduce bias from extreme symptom durations, we performed the requested sensitivity analysis and excluded patients with disease duration < 6 months and > 47 months [48]. This follows established ALS research methods, as duration extremes can distort progression-rate estimates. Importantly, our results remained consistent with the primary analysis, as only nine patients were excluded. Furthermore, individuals with ALS often experience dysphagia or rely on caregiver-assisted feeding, dietary recall may be prone to greater misreporting, introducing additional recall bias. Another limitation is the assessment of patients’ dietary intake through FFQ, which has moderate to low accuracy. Ultimately, in this study, ALS subtype and onset were not categorized, and we evaluated the association between the DII and body composition and disease progression in people living with ALS. Conclusion A diet with a high inflammatory index, which mainly includes animal proteins and dairy products, is associated with less disease progression, of course, this issue is influenced by several factors such as weight and physical activity. Also, the association between DII and anthropometric parameters in these patients is influenced by factors such as gender and disease severity. In general, a definitive conclusion cannot be made on the association of DII in ALS patients and there is a need for randomized clinical trials with appropriate design and sample size. Supplementary Information Supplementary Material 1. Supplementary Material 1.